CLAIMS

1. Use of udenafil or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a patient who has had a Fontan procedure, in which the medicament is formulated to be administered in a total daily dose from about 125 mg to about 175 mg of udenafil or a pharmaceutically acceptable salt thereof, in which the patient is in need of treatment to improve the patient's exercise capacity or to increase the likelihood of improving the patient's exercise capacity, as determined by maximum oxygen uptake at maximum exercise output (VO_2 measurement).

2. Use according to Claim 1, in which the patient who has had the Fontan procedure is a pediatric patient of about 12 to about 18 years of age.

3. Use according to Claim 1 or 2, in which the udenafil or pharmaceutically acceptable salt thereof is to be administered once a day.

4. Use according to Claim 1 or 2, in which the udenafil or pharmaceutically acceptable salt thereof is to be administered twice a day.

5. Use according to Claim 4, in which the effective dose of udenafil or pharmaceutically acceptable salt thereof is about 87.5 mg.

6. Use according to any preceding claim, in which the udenafil or pharmaceutically acceptable salt thereof is in an oral dosage form.

7. Use according to Claim 6, in which the oral dosage form is in a solid or semi-solid oral dosage form selected from the group consisting of: a tablet, a capsule, a gel, a liquid dispersion, a pill, a powder and a suspension.

8. Use according to Claim 7, in which the oral dosage form is a tablet.